Vanguard Portfolio Management discloses 5.26% stake in TG Therapeutics (NASDAQ: TGTX)

Rhea-AI Filing Summary

TG Therapeutics Inc reported a passive Schedule 13G ownership filing by Vanguard Portfolio Management. The filing shows 8,400,210 shares beneficially owned, representing 5.26% of common stock as of 03/31/2026. The filing states these holdings are held on behalf of Vanguard funds and managed accounts.

Insights

Institutional Ownership Analyst

Vanguard holds a >5% passive stake in TG Therapeutics as of 03/31/2026.

Vanguard Portfolio Management reports 8,400,210 shares (5.26%) with sole dispositive power over those shares and limited sole voting power of 126,231 shares. This indicates portfolio-level control of sales/decisions while voting rights are dispersed.

Disclosure notes these shares include positions across Vanguard funds and managed accounts; timing and any trading intent are not stated.

Regulatory Compliance Specialist

Filing conforms to Schedule 13G passive-investor disclosure rules.

The filing is made under the Schedule 13G framework and includes the required statements about holdings and affiliated Vanguard entities. It identifies dispositive and voting powers, and includes the signature dated 04/29/2026.

There is no indication of activist intent; the filing reads as a standard institutional disclosure under SEC Release No. 34-39538.

Key Figures

Shares beneficially owned: 8,400,210 shares Percent of class: 5.26% Sole voting power: 126,231 shares +2 more

5 metrics

Shares beneficially owned 8,400,210 shares as of 03/31/2026

Percent of class 5.26% ownership percentage reported in Schedule 13G

Sole voting power 126,231 shares voting power reported in Item 4

Sole dispositive power 8,400,210 shares dispositive power reported in Item 4

Filing signature date 04/29/2026 signature by Ashley Grim

Key Terms

Schedule 13G, Beneficially owned, Sole dispositive power, Sole voting power

4 terms

Schedule 13G regulatory

"passive investor disclosure filed under Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"amount beneficially owned: 8400210"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"sole power to dispose or to direct the disposition of: 8400210"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Sole voting power regulatory

"sole power to vote or to direct the vote: 126,231"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TG Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

88322Q108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88322Q108

1

Names of Reporting Persons

Vanguard Portfolio Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 126,231.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,400,210.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,400,210.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.26 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TG Therapeutics Inc
(b)	Address of issuer's principal executive offices: 2 Gansevoort Street, 9th Floor, New York, NY, 10014
Item 2.
(a)	Name of person filing: Vanguard Portfolio Management
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 88322Q108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8400210
(b)	Percent of class: 5.26 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 126231
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8400210
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Vanguard Portfolio Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vanguard Portfolio Management

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	04/29/2026

FAQ

Who filed the Schedule 13G for TGTX?

Vanguard Portfolio Management filed the Schedule 13G. The filing is signed by Ashley Grim and dated 04/29/2026, reporting holdings as of 03/31/2026.

How many TG Therapeutics shares does Vanguard report owning?

Vanguard reports beneficial ownership of 8,400,210 shares of TG Therapeutics common stock, equal to 5.26% of the class, as stated in the filing dated 03/31/2026.

What voting and dispositive powers does Vanguard report for TGTX shares?

The filing shows Vanguard has sole voting power over 126,231 shares and sole dispositive power over 8,400,210 shares, with no shared voting or dispositive powers reported.

Are Vanguard's holdings held for Vanguard funds or clients?

Yes. The filing states these shares include positions held by Vanguard funds and managed accounts over which Vanguard Portfolio Management and affiliates exercise dispositive authority.